MX2023005864A - Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2). - Google Patents
Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2).Info
- Publication number
- MX2023005864A MX2023005864A MX2023005864A MX2023005864A MX2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A MX 2023005864 A MX2023005864 A MX 2023005864A
- Authority
- MX
- Mexico
- Prior art keywords
- targeting agent
- her2
- her2 targeting
- fragment
- antigen
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020198044 | 2020-11-30 | ||
| JP2021110912 | 2021-07-02 | ||
| PCT/JP2021/043538 WO2022114163A1 (ja) | 2020-11-30 | 2021-11-29 | Her2標的化剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023005864A true MX2023005864A (es) | 2023-06-05 |
Family
ID=81754499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023005864A MX2023005864A (es) | 2020-11-30 | 2021-11-29 | Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2). |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20240002531A1 (enExample) |
| EP (1) | EP4253420A4 (enExample) |
| JP (2) | JP7393774B2 (enExample) |
| KR (1) | KR20230114747A (enExample) |
| AU (1) | AU2021387127A1 (enExample) |
| CA (1) | CA3199473A1 (enExample) |
| IL (1) | IL303154A (enExample) |
| MX (1) | MX2023005864A (enExample) |
| TW (1) | TW202229359A (enExample) |
| WO (1) | WO2022114163A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118871471A (zh) | 2022-04-08 | 2024-10-29 | 菲特治疗公司 | 用于肿瘤靶向的嵌合抗原受体 |
| AU2023249802A1 (en) * | 2022-04-08 | 2024-10-24 | Fate Therapeutics, Inc. | Cells having solid tumor targeting backbone and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| SI2330131T1 (sl) | 2009-12-07 | 2015-02-27 | Fundacio Privada Institucio Catalana De Recerca I Estudis Avancants | Protitelesa proti HER2 skrajšani varianti CTF-611 |
| WO2012047427A2 (en) * | 2010-08-31 | 2012-04-12 | The Regents Of The University Of California | Antibodies for botulinum neurotoxins |
| WO2019246021A1 (en) * | 2018-06-18 | 2019-12-26 | Dxdiscovery, Inc. | Methods and compositions for pertussis diagnosis |
| CN118871471A (zh) * | 2022-04-08 | 2024-10-29 | 菲特治疗公司 | 用于肿瘤靶向的嵌合抗原受体 |
-
2021
- 2021-11-29 JP JP2022565479A patent/JP7393774B2/ja active Active
- 2021-11-29 AU AU2021387127A patent/AU2021387127A1/en active Pending
- 2021-11-29 WO PCT/JP2021/043538 patent/WO2022114163A1/ja not_active Ceased
- 2021-11-29 EP EP21898135.5A patent/EP4253420A4/en active Pending
- 2021-11-29 IL IL303154A patent/IL303154A/en unknown
- 2021-11-29 US US18/038,185 patent/US20240002531A1/en active Pending
- 2021-11-29 TW TW110144472A patent/TW202229359A/zh unknown
- 2021-11-29 MX MX2023005864A patent/MX2023005864A/es unknown
- 2021-11-29 KR KR1020237017469A patent/KR20230114747A/ko active Pending
- 2021-11-29 CA CA3199473A patent/CA3199473A1/en active Pending
-
2023
- 2023-08-04 US US18/365,828 patent/US11981747B1/en active Active
- 2023-11-16 JP JP2023195187A patent/JP2024020436A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JPWO2022114163A1 (enExample) | 2022-06-02 |
| TW202229359A (zh) | 2022-08-01 |
| US20240002531A1 (en) | 2024-01-04 |
| WO2022114163A1 (ja) | 2022-06-02 |
| EP4253420A1 (en) | 2023-10-04 |
| JP2024020436A (ja) | 2024-02-14 |
| KR20230114747A (ko) | 2023-08-01 |
| EP4253420A4 (en) | 2024-11-06 |
| AU2021387127A1 (en) | 2023-06-22 |
| IL303154A (en) | 2023-07-01 |
| US11981747B1 (en) | 2024-05-14 |
| CA3199473A1 (en) | 2022-06-02 |
| JP7393774B2 (ja) | 2023-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2020236817A3 (en) | Mcl-1 inhibitor antibody-drug conjugates and methods of use | |
| WO2021227307A8 (zh) | 抗cd73抗体及其用途 | |
| MY205758A (en) | Anti-nkg2a antibodies and uses thereof | |
| MX2024013016A (es) | Anticuerpos anti-pd1 para usarse en el tratamiento del cancer | |
| PH12019501330A1 (en) | Antibody drug conjugates for ablating hematopoietic stem cells | |
| MX2014001373A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| UA106194C2 (ru) | Диагностика и лечение рака с применением антитела к ereg | |
| MX348581B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer. | |
| WO2021090062A8 (en) | Anti-mesothelin eribulin antibody-drug conjugates and methods of use | |
| MX2019013753A (es) | Combinaciones de inmunoconjugados anti-folr1 y anticuerpo anti-pd-1. | |
| MX2021010453A (es) | Conjugados anticuerpo-farmaco que comprenden anticuerpos contra dlk1 humana y uso de estos. | |
| AU2020212767A8 (en) | Combined pharmaceutical composition for treating tumor | |
| WO2022034524A3 (en) | Antibodies against ilt2 and use thereof | |
| MX2023005864A (es) | Agente dirigido al receptor 2 del factor de crecimiento epidermico humano (her2). | |
| WO2021207433A3 (en) | Epitopes of sars-cov-2 neutralizing antibodies | |
| MY209791A (en) | Anti-cd79b antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| ZA202308896B (en) | Antibodies binding trop2 and uses thereof | |
| MX2025001452A (es) | Anticuerpos anti-ccr8 y metodos de uso | |
| ZA202408388B (en) | Antibodies targeting sirp-alpha and uses thereof | |
| MX2023013726A (es) | Anticuerpos multiespecificos anti-cea y anti-cd137 y metodos de uso. | |
| UY38265A (es) | Conjugados anticuerpo droga para ablación de células madre hematopoyéticas | |
| IL242791B (en) | Antibodies against the toxin ricin | |
| MX2025004751A (es) | Anticuerpos anti molecula de adhesion celular l1 (l1-cam) y sus usos para aplicaciones diagnosticas y terapeuticas | |
| MX2025001042A (es) | Formulaciones de anticuerpos contra tl1a | |
| WO2020033926A3 (en) | Antibodies that bind cd277 and uses thereof |